{
"info": {
"nct_id": "NCT00422682",
"official_title": "A Phase 1B, Open-Label, Dose Escalation Study Evaluating the Safety of BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors",
"inclusion_criteria": "* ≥ 18 years old with a histologically or cytologically documented, advanced solid tumor\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1\n* Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (without granulocyte colony-stimulating factor [G-CSF] support within 2 weeks of study day 1); platelet count ≥ 100.0 x 10^9/L (without transfusion within 2 weeks of study day 1); and hemoglobin ≥ 9.0 g/dL (erythropoietic agents allowed)\n* At least a 14-day period from end of last dose of chemotherapy received\n* Any prior toxicity from prior chemotherapeutic treatment recovered to ≤ grade 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Subject enrolled in another investigational device or drug trial, or is receiving other investigational agents\n* Hematological malignancies\n* Symptomatic or untreated brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation, and corticosteroids.\n* History of seizure disorder\n* Myocardial infarction (MI) within 6 months of study day 1, unstable angina, congestive heart failure (CHF) with New York Heart Association (NYHA) > class II, or uncontrolled hypertension\n* Concurrent or prior (within 7 days of study day 1) anticoagulation therapy (low dose for port maintenance allowed)\n* Specified concomitant medications\n* Serum creatinine > 1.5 x upper limit of normal (ULN)\n* Elevated liver enzymes (AST/ALT) > 2.5 x ULN, or > 5.0 x ULN if secondary to liver metastases; alkaline phosphatase > 2.5 x ULN or > 5.0 x ULN if secondary to liver or bone metastases; total bilirubin > 1.5 x ULN\n* Radiation therapy within 14 days of study day 1\n* Antibody therapy for the treatment of an underlying malignancy within 14 days of study day 1\n* Concurrent radiation therapy is not permitted throughout the course of the study",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"identified_line": {
"line": "* ≥ 18 years old with a histologically or cytologically documented, advanced solid tumor",
"criterions": [
{
"exact_snippets": "≥ 18 years old",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
},
{
"exact_snippets": "histologically or cytologically documented",
"criterion": "tumor documentation",
"requirement": {
"requirement_type": "method",
"expected_value": [
"histologically",
"cytologically"
]
}
},
{
"exact_snippets": "advanced solid tumor",
"criterion": "tumor type",
"requirement": {
"requirement_type": "stage",
"expected_value": "advanced"
}
},
{
"exact_snippets": "advanced solid tumor",
"criterion": "tumor type",
"requirement": {
"requirement_type": "type",
"expected_value": "solid"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "≥ 18 years old",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
},
{
"exact_snippets": "histologically or cytologically documented",
"criterion": "tumor documentation",
"requirement": {
"requirement_type": "method",
"expected_value": [
"histologically",
"cytologically"
]
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "advanced solid tumor",
"criterion": "tumor type",
"requirement": {
"requirement_type": "stage",
"expected_value": "advanced"
}
},
{
"exact_snippets": "advanced solid tumor",
"criterion": "tumor type",
"requirement": {
"requirement_type": "type",
"expected_value": "solid"
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (without granulocyte colony-stimulating factor [G-CSF] support within 2 weeks of study day 1); platelet count ≥ 100.0 x 10^9/L (without transfusion within 2 weeks of study day 1); and hemoglobin ≥ 9.0 g/dL (erythropoietic agents allowed)",
"criterions": [
{
"exact_snippets": "Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (without granulocyte colony-stimulating factor [G-CSF] support within 2 weeks of study day 1)",
"criterion": "absolute neutrophil count (ANC)",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1.5,
"unit": "x 10^9/L"
}
}
},
{
"exact_snippets": "Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (without granulocyte colony-stimulating factor [G-CSF] support within 2 weeks of study day 1)",
"criterion": "absolute neutrophil count (ANC)",
"requirement": {
"requirement_type": "support",
"expected_value": false
}
},
{
"exact_snippets": "platelet count ≥ 100.0 x 10^9/L (without transfusion within 2 weeks of study day 1)",
"criterion": "platelet count",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 100.0,
"unit": "x 10^9/L"
}
}
},
{
"exact_snippets": "platelet count ≥ 100.0 x 10^9/L (without transfusion within 2 weeks of study day 1)",
"criterion": "platelet count",
"requirement": {
"requirement_type": "transfusion",
"expected_value": false
}
},
{
"exact_snippets": "hemoglobin ≥ 9.0 g/dL (erythropoietic agents allowed)",
"criterion": "hemoglobin",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 9.0,
"unit": "g/dL"
}
}
},
{
"exact_snippets": "hemoglobin ≥ 9.0 g/dL (erythropoietic agents allowed)",
"criterion": "hemoglobin",
"requirement": {
"requirement_type": "erythropoietic agents",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (without granulocyte colony-stimulating factor [G-CSF] support within 2 weeks of study day 1)",
"criterion": "absolute neutrophil count (ANC)",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1.5,
"unit": "x 10^9/L"
}
}
},
{
"exact_snippets": "Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (without granulocyte colony-stimulating factor [G-CSF] support within 2 weeks of study day 1)",
"criterion": "absolute neutrophil count (ANC)",
"requirement": {
"requirement_type": "support",
"expected_value": false
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "platelet count ≥ 100.0 x 10^9/L (without transfusion within 2 weeks of study day 1)",
"criterion": "platelet count",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 100.0,
"unit": "x 10^9/L"
}
}
},
{
"exact_snippets": "platelet count ≥ 100.0 x 10^9/L (without transfusion within 2 weeks of study day 1)",
"criterion": "platelet count",
"requirement": {
"requirement_type": "transfusion",
"expected_value": false
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "hemoglobin ≥ 9.0 g/dL (erythropoietic agents allowed)",
"criterion": "hemoglobin",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 9.0,
"unit": "g/dL"
}
}
},
{
"exact_snippets": "hemoglobin ≥ 9.0 g/dL (erythropoietic agents allowed)",
"criterion": "hemoglobin",
"requirement": {
"requirement_type": "erythropoietic agents",
"expected_value": true
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* At least a 14-day period from end of last dose of chemotherapy received",
"criterions": [
{
"exact_snippets": "At least a 14-day period from end of last dose of chemotherapy",
"criterion": "time since last chemotherapy dose",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 14,
"unit": "days"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "At least a 14-day period from end of last dose of chemotherapy",
"criterion": "time since last chemotherapy dose",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 14,
"unit": "days"
}
}
}
]
}
},
{
"identified_line": {
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
}
},
{
"identified_line": {
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
}
}
],
"exclusion_lines": [
{
"identified_line": {
"line": "* Hematological malignancies",
"criterions": [
{
"exact_snippets": "Hematological malignancies",
"criterion": "hematological malignancies",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "Hematological malignancies",
"criterion": "hematological malignancies",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
}
},
{
"identified_line": {
"line": "* Symptomatic or untreated brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation, and corticosteroids.",
"criterions": [
{
"exact_snippets": "Symptomatic or untreated brain metastases",
"criterion": "brain metastases",
"requirement": {
"requirement_type": "symptomatic",
"expected_value": true
}
},
{
"exact_snippets": "Symptomatic or untreated brain metastases",
"criterion": "brain metastases",
"requirement": {
"requirement_type": "treatment status",
"expected_value": "untreated"
}
},
{
"exact_snippets": "requiring concurrent treatment, inclusive of but not limited to surgery, radiation, and corticosteroids",
"criterion": "concurrent treatment",
"requirement": {
"requirement_type": "types",
"expected_value": [
"surgery",
"radiation",
"corticosteroids"
]
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Symptomatic or untreated brain metastases",
"criterion": "brain metastases",
"requirement": {
"requirement_type": "symptomatic",
"expected_value": true
}
},
{
"exact_snippets": "requiring concurrent treatment, inclusive of but not limited to surgery, radiation, and corticosteroids",
"criterion": "concurrent treatment",
"requirement": {
"requirement_type": "types",
"expected_value": [
"surgery",
"radiation",
"corticosteroids"
]
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "Symptomatic or untreated brain metastases",
"criterion": "brain metastases",
"requirement": {
"requirement_type": "treatment status",
"expected_value": "untreated"
}
},
{
"exact_snippets": "requiring concurrent treatment, inclusive of but not limited to surgery, radiation, and corticosteroids",
"criterion": "concurrent treatment",
"requirement": {
"requirement_type": "types",
"expected_value": [
"surgery",
"radiation",
"corticosteroids"
]
}
}
]
}
]
}
]
}
},
{
"identified_line": {
"line": "* History of seizure disorder",
"criterions": [
{
"exact_snippets": "History of seizure disorder",
"criterion": "seizure disorder",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "History of seizure disorder",
"criterion": "seizure disorder",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "* Myocardial infarction (MI) within 6 months of study day 1, unstable angina, congestive heart failure (CHF) with New York Heart Association (NYHA) > class II, or uncontrolled hypertension",
"criterions": [
{
"exact_snippets": "Myocardial infarction (MI) within 6 months of study day 1",
"criterion": "myocardial infarction (MI)",
"requirement": {
"requirement_type": "time since event",
"expected_value": {
"operator": "<=",
"value": 6,
"unit": "months"
}
}
},
{
"exact_snippets": "unstable angina",
"criterion": "unstable angina",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "congestive heart failure (CHF) with New York Heart Association (NYHA) > class II",
"criterion": "congestive heart failure (CHF)",
"requirement": {
"requirement_type": "New York Heart Association (NYHA) class",
"expected_value": {
"operator": ">",
"value": 2,
"unit": "class"
}
}
},
{
"exact_snippets": "uncontrolled hypertension",
"criterion": "uncontrolled hypertension",
"requirement": {
"requirement_type": "control status",
"expected_value": "uncontrolled"
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Myocardial infarction (MI) within 6 months of study day 1",
"criterion": "myocardial infarction (MI)",
"requirement": {
"requirement_type": "time since event",
"expected_value": {
"operator": "<=",
"value": 6,
"unit": "months"
}
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "unstable angina",
"criterion": "unstable angina",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "congestive heart failure (CHF) with New York Heart Association (NYHA) > class II",
"criterion": "congestive heart failure (CHF)",
"requirement": {
"requirement_type": "New York Heart Association (NYHA) class",
"expected_value": {
"operator": ">",
"value": 2,
"unit": "class"
}
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "uncontrolled hypertension",
"criterion": "uncontrolled hypertension",
"requirement": {
"requirement_type": "control status",
"expected_value": "uncontrolled"
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Concurrent or prior (within 7 days of study day 1) anticoagulation therapy (low dose for port maintenance allowed)",
"criterions": [
{
"exact_snippets": "Concurrent or prior (within 7 days of study day 1) anticoagulation therapy",
"criterion": "anticoagulation therapy",
"requirement": {
"requirement_type": "timing",
"expected_value": "concurrent or prior (within 7 days of study day 1)"
}
},
{
"exact_snippets": "low dose for port maintenance allowed",
"criterion": "anticoagulation therapy",
"requirement": {
"requirement_type": "dose",
"expected_value": "low dose for port maintenance allowed"
}
}
]
},
"logical_structure": {
"condition": {
"exact_snippets": "Concurrent or prior (within 7 days of study day 1) anticoagulation therapy",
"criterion": "anticoagulation therapy",
"requirement": {
"requirement_type": "timing",
"expected_value": "concurrent or prior (within 7 days of study day 1)"
}
},
"then_criteria": {
"not_criteria": {
"exact_snippets": "low dose for port maintenance allowed",
"criterion": "anticoagulation therapy",
"requirement": {
"requirement_type": "dose",
"expected_value": "low dose for port maintenance allowed"
}
}
},
"else_criteria": null
}
},
{
"identified_line": {
"line": "* Specified concomitant medications",
"criterions": [
{
"exact_snippets": "Specified concomitant medications",
"criterion": "concomitant medications",
"requirement": {
"requirement_type": "specification",
"expected_value": "specified"
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "Specified concomitant medications",
"criterion": "concomitant medications",
"requirement": {
"requirement_type": "specification",
"expected_value": "specified"
}
}
}
},
{
"identified_line": {
"line": "* Serum creatinine > 1.5 x upper limit of normal (ULN)",
"criterions": [
{
"exact_snippets": "Serum creatinine > 1.5 x upper limit of normal (ULN)",
"criterion": "serum creatinine",
"requirement": {
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 1.5,
"unit": "x ULN"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Serum creatinine > 1.5 x upper limit of normal (ULN)",
"criterion": "serum creatinine",
"requirement": {
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 1.5,
"unit": "x ULN"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Elevated liver enzymes (AST/ALT) > 2.5 x ULN, or > 5.0 x ULN if secondary to liver metastases; alkaline phosphatase > 2.5 x ULN or > 5.0 x ULN if secondary to liver or bone metastases; total bilirubin > 1.5 x ULN",
"criterions": [
{
"exact_snippets": "Elevated liver enzymes (AST/ALT) > 2.5 x ULN, or > 5.0 x ULN if secondary to liver metastases",
"criterion": "liver enzymes (AST/ALT)",
"requirement": {
"requirement_type": "level",
"expected_value": {
"comparisons": [
{
"operator": ">",
"value": 2.5,
"unit": "x ULN"
}
]
}
}
},
{
"exact_snippets": "Elevated liver enzymes (AST/ALT) > 2.5 x ULN, or > 5.0 x ULN if secondary to liver metastases",
"criterion": "liver enzymes (AST/ALT)",
"requirement": {
"requirement_type": "level",
"expected_value": {
"comparisons": [
{
"operator": ">",
"value": 5.0,
"unit": "x ULN"
}
]
}
}
},
{
"exact_snippets": "alkaline phosphatase > 2.5 x ULN or > 5.0 x ULN if secondary to liver or bone metastases",
"criterion": "alkaline phosphatase",
"requirement": {
"requirement_type": "level",
"expected_value": {
"comparisons": [
{
"operator": ">",
"value": 2.5,
"unit": "x ULN"
}
]
}
}
},
{
"exact_snippets": "alkaline phosphatase > 2.5 x ULN or > 5.0 x ULN if secondary to liver or bone metastases",
"criterion": "alkaline phosphatase",
"requirement": {
"requirement_type": "level",
"expected_value": {
"comparisons": [
{
"operator": ">",
"value": 5.0,
"unit": "x ULN"
}
]
}
}
},
{
"exact_snippets": "total bilirubin > 1.5 x ULN",
"criterion": "total bilirubin",
"requirement": {
"requirement_type": "level",
"expected_value": {
"comparisons": [
{
"operator": ">",
"value": 1.5,
"unit": "x ULN"
}
]
}
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"or_criteria": [
{
"condition": {
"exact_snippets": "Elevated liver enzymes (AST/ALT) > 2.5 x ULN, or > 5.0 x ULN if secondary to liver metastases",
"criterion": "liver enzymes (AST/ALT)",
"requirement": {
"requirement_type": "level",
"expected_value": {
"comparisons": [
{
"operator": ">",
"value": 5.0,
"unit": "x ULN"
}
]
}
}
},
"then_criteria": null,
"else_criteria": {
"exact_snippets": "Elevated liver enzymes (AST/ALT) > 2.5 x ULN, or > 5.0 x ULN if secondary to liver metastases",
"criterion": "liver enzymes (AST/ALT)",
"requirement": {
"requirement_type": "level",
"expected_value": {
"comparisons": [
{
"operator": ">",
"value": 2.5,
"unit": "x ULN"
}
]
}
}
}
},
{
"condition": {
"exact_snippets": "alkaline phosphatase > 2.5 x ULN or > 5.0 x ULN if secondary to liver or bone metastases",
"criterion": "alkaline phosphatase",
"requirement": {
"requirement_type": "level",
"expected_value": {
"comparisons": [
{
"operator": ">",
"value": 5.0,
"unit": "x ULN"
}
]
}
}
},
"then_criteria": null,
"else_criteria": {
"exact_snippets": "alkaline phosphatase > 2.5 x ULN or > 5.0 x ULN if secondary to liver or bone metastases",
"criterion": "alkaline phosphatase",
"requirement": {
"requirement_type": "level",
"expected_value": {
"comparisons": [
{
"operator": ">",
"value": 2.5,
"unit": "x ULN"
}
]
}
}
}
}
]
},
{
"exact_snippets": "total bilirubin > 1.5 x ULN",
"criterion": "total bilirubin",
"requirement": {
"requirement_type": "level",
"expected_value": {
"comparisons": [
{
"operator": ">",
"value": 1.5,
"unit": "x ULN"
}
]
}
}
}
]
}
},
{
"identified_line": {
"line": "* Radiation therapy within 14 days of study day 1",
"criterions": [
{
"exact_snippets": "Radiation therapy within 14 days of study day 1",
"criterion": "radiation therapy",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": "<=",
"value": 14,
"unit": "days"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Radiation therapy within 14 days of study day 1",
"criterion": "radiation therapy",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": "<=",
"value": 14,
"unit": "days"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Antibody therapy for the treatment of an underlying malignancy within 14 days of study day 1",
"criterions": [
{
"exact_snippets": "Antibody therapy for the treatment of an underlying malignancy within 14 days of study day 1",
"criterion": "antibody therapy",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": "<=",
"value": 14,
"unit": "days"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Antibody therapy for the treatment of an underlying malignancy within 14 days of study day 1",
"criterion": "antibody therapy",
"requirement": {
"requirement_type": "time since last treatment",
"expected_value": {
"operator": "<=",
"value": 14,
"unit": "days"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Concurrent radiation therapy is not permitted throughout the course of the study",
"criterions": [
{
"exact_snippets": "Concurrent radiation therapy is not permitted",
"criterion": "concurrent radiation therapy",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Concurrent radiation therapy is not permitted",
"criterion": "concurrent radiation therapy",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
}
}
],
"miscellaneous_lines": [],
"failed_inclusion": [
{
"identified_line": {
"line": "* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1",
"criterion": "ECOG performance status",
"requirement": {
"requirement_type": "performance status",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "N/A"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of \u0010 1",
"criterion": "ECOG performance status",
"requirement": {
"requirement_type": "performance status",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "N/A"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Any prior toxicity from prior chemotherapeutic treatment recovered to ≤ grade 1",
"criterions": [
{
"exact_snippets": "Any prior toxicity from prior chemotherapeutic treatment recovered to ≤ grade 1",
"criterion": "toxicity from prior chemotherapeutic treatment",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "grade"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Any prior toxicity from prior chemotherapeutic treatment recovered to \u0010 grade 1",
"criterion": "toxicity from prior chemotherapeutic treatment",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "grade"
}
}
}
]
}
}
],
"failed_exclusion": [
{
"identified_line": {
"line": "* Subject enrolled in another investigational device or drug trial, or is receiving other investigational agents",
"criterions": [
{
"exact_snippets": "Subject enrolled in another investigational device or drug trial",
"criterion": "enrollment in another investigational trial",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "receiving other investigational agents",
"criterion": "receiving investigational agents",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Subject enrolled in another investigational device or drug trial",
"criterion": "enrollment in another investigational trial",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "receiving other investigational agents",
"criterion": "receiving investigational agents",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
}
],
"failed_miscellaneous": []
}